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ABSTRACT 27 
Proteus mirabilis forms dense crystalline biofilms on catheter surfaces that occlude 28 
urine flow leading to serious clinical complications in long-term catheterised patients, 29 
but there are presently no truly effective approaches to control catheter blockage by 30 
this organism. This study evaluated the potential for bacteriophage therapy to control 31 
P. mirabilis infection and prevent catheter blockage. Representative in vitro models of 32 
the catheterised urinary tract, simulating a complete closed drainage system as used 33 
in clinical practice, were employed to evaluate the performance of phage therapy in 34 
preventing blockage. Models mimicking either an established infection, or early 35 
colonisation of the catheterised urinary tract, were treated with a single dose of a 3 36 
phage cocktail, and the impact on time taken for catheters to block, as well as levels 37 
of crystalline biofilm formation, were measured. In models of established infection 38 
phage treatment significantly increased time taken for catheters to block (~3-fold) 39 
compared to untreated controls. However, in models simulating early stage infection 40 
phage treatment eradicated P. mirabilis and prevented blockage entirely. Analysis of 41 
catheters from models of established infection, 10 hours after phage application, 42 
demonstrated that phage significantly reduced crystalline biofilm formation, but did 43 
not significantly reduce the level of planktonic cells in the residual “bladder” urine. 44 
Taken together, these results show that bacteriophage constitute a promising 45 
strategy for the prevention of catheter blockage, but that methods to deliver phage in 46 
sufficient numbers and within a key therapeutic window (early infection) will also be 47 
important to the successful application of phage to this problem. 48 
 49 
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INTRODUCTION 51 
A frequent complication associated with long-term urethral catheterisation is 52 
encrustation and blockage of catheters due to infection with Proteus mirabilis, which 53 
can be isolated from around 45% of catheter associated urinary tract infections 54 
(CAUTI) (1, 2). Blockage stems from the ability of P. mirabilis to form dense biofilms 55 
on catheter surfaces, and the production of a potent urease enzyme which generates 56 
ammonia through hydrolysis of urea (1, 3, 4). Ammonia production elevates urinary 57 
pH causing the precipitation of calcium and magnesium phosphates, and the 58 
subsequent formation of crystals which become trapped within developing biofilms (1, 59 
5). Once embedded in the biofilm, crystal growth is stabilised and enhanced by the 60 
biofilm matrix (6, 7). As this process continues the biofilm gradually becomes 61 
mineralised, leading to development of extensive crystalline biofilm structures which 62 
ultimately block catheters (1, 5). If unnoticed, blockage can lead to reflux of infected 63 
urine to the upper urinary tract, and the onset of serious clinical complications 64 
including pyelonephritis, septicaemia, and shock (1, 8). 65 
 66 
Although catheters containing antimicrobial coatings are currently available, their 67 
efficacy in preventing infection during even short-term use remains questionable, and 68 
all available catheter types remain susceptible to P. mirabilis encrustation and 69 
blockage (9, 10). P. mirabilis is also extremely difficult to eliminate once established 70 
in the catheterised urinary tract and often responds poorly to conventional antibiotic 71 
therapy. It can persist despite multiple catheter changes or periods without 72 
catheterisation, and causes chronic infection and blockage in many patients (8, 9, 73 
11). There are presently no truly effective strategies for the control of P. mirabilis 74 
CAUTI and associated blockage, and the development of new approaches is urgently 75 
required. The aim of this study was to determine if bacteriophage (phage) therapy 76 
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may constitute a viable approach to the prevention of catheter encrustation and 77 
blockage. 78 
 79 
MATERIALS AND METHODS 80 
Bacterial strains, media, routine culture. Clinical isolates of P. mirabilis 81 
(designated RS1 and RS3) used in this study were obtained from the Royal Sussex 82 
County Hospital, and all were derived from urinary tract infections. All chemicals, 83 
reagents and growth media were obtained either from Fisher Scientific UK, Oxoid 84 
UK, or Sigma UK unless otherwise stated. Bacteria were routinely cultured in 85 
Lysogeny-Broth Derivative Broth (LBDB) medium (5 g/l Yeast Extract, 10 g/l 86 
Vegetable peptone Nº1, 10 g/l Sodium Chloride) at 37°C with shaking, or on LBDB 87 
solidified by the addition of 15 g/l Technical agar (LBDA). Soft agar overlays, used for 88 
phage enrichments, purification and enumeration, were derived from LBDA (S-LBDA) 89 
and contained 5 g/l Yeast extract, 10 g/l Vegetable peptone Nº1, and 5.75 g/l 90 
Technical agar, and was kept molten at 45ºC for use in agar overlays. The artificial 91 
urine (AU) medium previously described by Stickler et al. (12), was initially prepared 92 
as a 5X concentrated stock solution containing sodium disulfate (11.5 g/l), 93 
magnesium chloride (hexahydrate) (3.25 g/l), sodium chloride (23 g/l), trisodium 94 
citrate (3.25 g/l), sodium oxalate (0.1 g/l), potassium dihydrogen orthophosphate (14 95 
g/l), potassium chloride (8 g/l), ammonium chloride (5 g/l), calcium chloride dihydrate 96 
(3.25 g/l), urea (125 g/l), gelatin (25 g/l), and tryptone soya broth (5 g/l). Stock 97 
solutions of urea and calcium chloride dihydrate were sterilised separately by 98 
membrane filtration (0.45 µm; Sartorius, United Kingdom) while other components 99 
were sterilised by autoclaving. For use in bladder models all components were 100 
combined and diluted to 1X strength using sterile deionised water, with the final pH 101 
adjusted to 6.1. 102 
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 103 
Phage isolation and purification. Phages were isolated from sewage collected from 104 
wastewater treatment plants in the UK (Anglian water, Luton area). For initial 105 
enrichments of P. mirabilis phage 387.5 ml of LBDB was mixed with 100 ml of 106 
sewage, and inoculated with 2.5 ml of host growing cultures of P. mirabilis. 107 
Enrichments were incubated statically overnight at 37ºC and the following day 10 ml 108 
aliquots were recovered, centrifuged (3000 X g for 30 min), and supernatants filtered 109 
into fresh sterile tubes using 0.22 µm pore syringe filters (Sartorius, United Kingdom). 110 
100 µl of filtered enrichment was mixed with 100 µl of a P. mirabilis exponential 111 
phase growing culture to be used as phage host (either clinical isolate RS1 or RS3), 112 
combined with 3 ml molten S-LBDA, swirled gently, and immediately poured over the 113 
surface of an LBDA plate. Plates were incubated at 37ºC for 18-20 h. Phage 114 
replication was identified by zones of lysis (plaques) in the confluent bacterial growth 115 
within S-LBDA overlays. To isolate and purify distinct phage individual plaques were 116 
picked off using Pasteur pipettes, and resuspended in 300 µl SM Buffer (100 mM 117 
NaCl, 10 mM MgSO4.7H2O, 50 mM Tris-HCl pH 7.5, 0.01% gelatine). The resulting 118 
phage suspensions were serially diluted in SM Buffer (10-3 to 10-6), and dilutions used 119 
to repeat agar overlays with host strains of P. mirabilis used in initial isolation. To 120 
ensure clonality of phage types, this process was repeated a further 5 times until 121 
bacterial lawns showed homogeneity of plaque morphology. Finally, an individual 122 
plaque was picked off and resuspended in SM buffer for use in subsequent 123 
experiments. These final clonal phage suspensions were stored at 4ºC until required. 124 
 125 
Preparation of high titre phage stocks. Phage were propagated on P. mirabilis 126 
RS1 host and high titre stocks obtained. Briefly, 100 μl of phage suspension and 100 127 
μl of host growing culture were mixed, combined with 3 ml of molten S-LBDA, swirled 128 
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gently and poured onto agar plates. After a static overnight incubation at 37°C, plates 129 
displaying confluent lysis were selected and 3 ml of SM buffer supplemented with 2% 130 
(v/v) chloroform (to lyse remaining bacterial cells and maximize yield) were added 131 
before incubation at 37°C for 4 h. High-titre phage solution was removed from the 132 
plates, centrifuged (8,000 X g for 10 min) to remove cell debris, and then filter-133 
sterilised (pore size, 0.22 μm) and stored at 4°C.  134 
 135 
In vitro bladder models. In vitro bladder models, originally described by Stickler et 136 
al. (12), were set up and operated as described previously (13). The key features of 137 
models are illustrated in Figure 1, and consist of a double-walled glass chamber (the 138 
bladder) maintained at 37°C by a water jacket supplied from a circulating water bath. 139 
Size 14 French all-silicone Foley catheters (Bard, United Kingdom) were used in all 140 
experiments, and are inserted into the “bladder” via an outlet in the base of the glass 141 
chamber, before retention balloons are inflated with 10 ml sterile water. Catheters 142 
were subsequently attached to a drainage bag to form a sterile closed drainage 143 
system, and AU medium supplied at a constant flow rate of 0.75 ml /min. P. mirabilis 144 
RS1 cell suspensions were inoculated directly into the residual bladder urine at either 145 
1010 cfu or 103 cfu representing late sage or early stage infection respectively, and 146 
flow suspended for 1h to permit cells to establish within the system. 45 min after 147 
bacterial inoculation, test models were treated with a single dose of 3 x 1010 pfu of a 148 
3 phage cocktail (1:1:1, 1010 pfu of each phage) in a volume of 1 ml, and flow 149 
restored 15 min later. The numbers of viable cells present in the residual bladder 150 
medium were enumerated at the start and end of experiments, and pH was also 151 
measured at the start and end of experiments by sampling the medium in the 152 
“bladder.” 153 
 154 
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Quantification of crystalline biofilm formation on catheter sections. To measure 155 
the levels of crystalline biofilm formation and catheter encrustation in control and 156 
phage treated models, the amount of calcium present on catheter sections removed 157 
from bladder models run for a set time (10 h) was quantified by flame photometry, 158 
described previously (13). Briefly, 1 cm catheter sections were submerged in 2 ml of 159 
an ammonium oxalate and oxalic acid solution (95% and 5% vol/vol respectively from 160 
0.1 M stock solutions), subject to vigorous mixing for 3 min, then incubated at room 161 
temperature for 30 min. Catheter sections were then removed, the remaining mixture 162 
centrifuged (3000 X g for 10 min) and the supernatant discarded. Pellets were 163 
resuspended in 5 ml perchloric acid (0.05 M), samples mixed thoroughly, centrifuged 164 
(3000 X g for 2 min), and supernatants recovered. Levels of calcium dissolved in 165 
supernatants were determined using a flame photometer (Corning, Flame 166 
Photometer 410), calibrated using calcium standards at 100, 75, 50 and 25 ppm.  167 
 168 
SEM of catheter cross sections. The thickness of biofilms and extent of 169 
encrustation on catheters recovered from timed models was visualised by SEM. 170 
Catheters were sectioned as shown in Fig. 4A, and mounted directly onto aluminium 171 
stubs using Leit adhesive carbon tabs (Agar Scientific, Stansted, United Kingdom). 172 
Mounted sections were stored overnight in a desiccator at RT then sputter coated 173 
with platinum using a Quorum Q150T ES system (Quorum Technologies, United 174 
Kingdom) and viewed using a Zeiss Evo LS15 microscope under high vacuum at an 175 
accelerating (EHT) voltage of 5 Kv and using a 5Q-BSD.  176 
 177 
Transmission electron microscopy of bacteriophage. Purified phage particles 178 
(109 pfu/ml) were immobilised on a 200 mesh Formvar/Carbon copper electron 179 
microscope grids (Agar Scientific, UK), and negatively stained with 2% 180 
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phosphotungstic acid (pH 7.4) (Sigma, UK). Phage were imaged by FEG-STEM 181 
using a Zeiss SIGMA FEG-SEM microscope at 20 Kv accelerating voltage, 20µm 182 
aperture, and 2.7 mm working distance. 183 
 184 
Analysis of Data. All statistical analysis was performed using Prism 6.0c For Mac 185 
OS X (Graphpad Software inc. USA; www.graphpad.com). Data was analysed using 186 
either Student’s t-test, or ANOVA with the Bonferroni multiple comparisons test. 187 
 188 
RESULTS 189 
Bacteriophage isolation and characterisation. Three lytic phage, designated 190 
ΦRS1-PmA, ΦRS1-PmB, and ΦRS3-PmA, were isolated from wastewater through 191 
enrichments against clinical isolates of P. mirabilis. These phage showed distinct but 192 
overlapping host ranges (against a panel of 51 clinical isolates; data not shown) and 193 
differences in plaque morphology (Fig. 2). All were observed to generate halos 194 
around plaques, indicative of polysaccharide depolymerise activity, and were 195 
classified as members of the Podoviridiae based on TEM observations of capsid 196 
morphology (Fig. 2). All three phage were included in a “cocktail” in equal proportions 197 
(1:1:1) for evaluation of phage therapy in representative models of the catheterised 198 
urinary tract. 199 
 200 
Effect of phage therapy on catheter blockage. Initial experiments replicated a 201 
worst-case scenario in which phage were used to treat an established infection (1010 202 
cfu P. mirabilis in bladder models). Under these conditions a single “dose” of the 203 
phage cocktail (1010 pfu, MOI 1:1 phage:bacteria) significantly extended the time 204 
taken for catheters to block (~3 fold) (Fig. 3). Because interventions affecting 205 
blockage under these highly challenging conditions are likely to have greater impact 206 
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when applied earlier in the infection process, we next evaluated the impact of the 207 
same phage “dose” in experiments replicating the early stages of infection (103 cfu P. 208 
mirabilis, MOI 1:10-7 phage:bacteria). Under these conditions, the phage cocktail 209 
completely prevented catheter blockage and eradicated infection, with models 210 
draining freely for > 8 days until media reserves were exhausted (Fig. 3). In contrast, 211 
catheters in corresponding control models developed substantial encrustation, and 212 
became blocked after ~2 days (Fig. 3). 213 
 214 
Effect of phage treatment on crystalline biofilm formation. To specifically 215 
evaluate the impact of phage treatment on crystalline biofilm formation, models of 216 
late stage infection were deactivated after 10 h, and levels of calcium on catheter 217 
sections quantified. This demonstrated that phage treatment significantly reduced 218 
levels of encrustation (Fig. 4A). These data were supported by direct SEM 219 
visualisation of catheter sections, which showed sections from models treated with 220 
phage to be devoid of visible crystalline deposits. This was in stark contrast to 221 
catheter sections from untreated models, which exhibited prominent encrustations 222 
(Fig. 4B). While these observations corresponded with a significant reduction in pH in 223 
treated models, the number of viable planktonic cells in residual urine from test or 224 
control models was not found to be significantly different (Fig. 4C,D).  225 
 226 
DISCUSSION 227 
Here we demonstrate the potential for bacteriophage to constitute an effective 228 
countermeasure for one of the most common and serious complications of long-term 229 
urethral catheterisation: encrustation and blockage. Our findings are congruent with 230 
previous studies examining the potential to control biofilm formation on urinary 231 
catheters using phage, where a reduction in biofilm formation by P. mirabilis, 232 
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Escherichia coli, Pseudomonas aeruginosa and Staphylococcus epidermidis has 233 
been reported when catheter sections were pretreated with phage suspensions (14, 234 
15, 16). More recently, Lehman and Donlan (17) have described phage pretreatment 235 
for control of mixed species biofilm formation (P. aeruginosa & P. mirabilis), and also 236 
evaluated encrustation of catheter sections. However, these previous studies were 237 
able to show a reduction, rather than complete prevention, of biofilm formation by 238 
uropathogens tested, and where P. mirabilis was used phage did not fully prevent 239 
encrustation (14, 16, 17).  240 
 241 
In contrast our data highlight the potential for a more dramatic impact of phage 242 
therapy in preventing blockage and resolution of P. mirabilis infection. Although 243 
specific attributes of the phage used in this study may be important to the outcome of 244 
bladder model experiments reported here, the differences in phage performance 245 
noted between this and other studies most likely relates to the high titres of phage 246 
achieved in bladder models, and delivery directly to residual bladder urine. In 247 
contrast, previous studies targeting P. mirabilis or other uropathogens have focused 248 
on the pretreatment of catheter sections with phage suspensions prior to use in 249 
models of biofilm formation (14, 15, 16, 17). As a result, the final titres of phage 250 
tested in these systems (and resulting MOIs established) was unclear, but likely to be 251 
substantially lower than those obtained in our models.  252 
 253 
In addition, previous evaluations of phage therapy for CAUTI have mainly been 254 
designed to evaluate the ability of phage to reduce biofilm formation in general, 255 
rather than prevent catheter blockage specifically. In this context, the focus of our 256 
study on blockage as a specific therapeutic end point, and the evaluation of phage 257 
using a full closed drainage system in the bladder model system is also a key 258 
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difference. This model provides an excellent representation of the catheterised 259 
urinary tract and assessment of phage therapy in this setting.  260 
 261 
In contrast, previous studies have used either simple static models of biofilm 262 
formation on catheter sections (14), or deployed models that do not use whole intact 263 
catheters or fully replicate the closed drainage system (15, 16, 17). While such 264 
models of infection clearly provide a useful and valid insight into the potential of 265 
phage therapy for CAUTI, and the control of bacterial biofilms in this setting, the 266 
encrustation and blockage of catheters is also governed by physical characteristics of 267 
distinct regions of catheters and the physicochemical forces that develop in the 268 
closed drainage system (1).  269 
 270 
Most notably, blockage typically occurs around the catheter eye-hole and the first few 271 
centimetres of the catheter, which provide more irregular surface topologies [arising 272 
from the manufacturing process] that are particularly supportive of bacterial 273 
colonisation, and are continually exposed to the sump of infected residual urine that 274 
accumulates in the bladder (1,12,13). Therefore, the bladder model system provides 275 
a particularly robust evaluation of interventions aimed at prevention of blockage and 276 
encrustation, and the use of this system strengthens the observations reported here 277 
around the potential of phage to prevent catheter blockage.  278 
 279 
Nevertheless, it is notable that phage were only able to fully prevent blockage when 280 
used in models of early stage infection. The simplest explanation for failure to prevent 281 
blockage in simulations of established infection is that the dose of phage used was 282 
insufficient to deal with the dense P. mirabilis population, and under MOIs 283 
established P. mirabilis growth and crystalline biofilm formation simply outstripped the 284 
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capacity of phage to eliminate infection. This may have been compounded by factors 285 
such as wash out of phage from model systems during the course of experiments, as 286 
well as the rapid elevation of urinary pH in models of late stage infection, which may 287 
reach pH 8 ~2-3 h after model activation.  288 
 289 
Conversely, the recovery of phage from models of early infection 8 days after model 290 
activation (albeit at low levels, ~20 pfu/ml), despite an apparent absence of host 291 
bacteria for the majority of this time and the far longer duration of these experiments 292 
compared with models of established infection, argues against washout as a 293 
significant factor. Under conditions of high pH it is possible phage may be inactivated 294 
or their ability to infect host cells reduced, leading to eventual therapeutic failure. 295 
Previous evaluations of P. mirabilis phage have indicated that these remain active 296 
even under conditions of high pH (17). Our own evaluation of specific phage used 297 
here confirms these remain capable of infection after exposure to high pH (data not 298 
shown), but the possibility that alterations to cell surface properties protects against 299 
infection with these specific phage at high pH cannot be excluded.  300 
 301 
Alternatively, the failure of phage to prevent blockage in late stage infection may be 302 
explained by the development of resistance to the phage used, and this has been 303 
observed in other studies of phage therapy for CAUTI over a similar time frame (16). 304 
Although the use of a three phage cocktail should guard against resistance, the 305 
phage used here have similar host range profiles, are all members of the Podoviridae 306 
family, and are yet to be characterised genetically. It is therefore possible that they 307 
constitute closely related phage types with comparable mechanisms of attachment 308 
and infection. This could allow the same mutation(s) in host bacteria to afford 309 
resistance to all three. In this context it is notable also that many key surface 310 
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structures of P. mirabilis that may be receptors for phage attachment are subject to 311 
phase variable gene expression (18), and it is therefore not unlikely that a small 312 
proportion of a given P. mirabilis population may be naturally immune to particular 313 
phage types, and selected for during phage treatment. 314 
 315 
Despite this, there is clear potential to address the issue of resistance by ensuring 316 
selection of phage binding distinct cell surface structures, and generating a greater 317 
understanding of the mechanisms underpinning phage:host interaction in P. mirabilis, 318 
particularly under conditions encountered in the catheterised urinary tract. 319 
Furthermore, the high MOIs achieved in models of early infection also raises the 320 
potential for the induction of lysis from without (LO), which could also explain the 321 
differences in efficacy of phage treatment in the two infection scenarios modelled. 322 
The induction of LO could be highly advantageous in control of P. mirabilis CAUTI 323 
and subsequent studies should explore if P. mirabilis phage used here can induce 324 
LO, and the applications of this to control of CAUTI. 325 
 326 
It was also clear from timed bladder model experiments that phage treatment 327 
significantly reduced levels of crystalline biofilm formation in models of established 328 
infection. Intriguingly, this work also suggests that the impact of phage treatment on 329 
P. mirabilis crystalline biofilm formation may not be solely attributable to a reduction 330 
in the number of planktonic cells available to participate in biofilm formation, since no 331 
statistically significant differences were observed in the number of viable planktonic 332 
cells in residual urine from test or control models at the 10h time point.  333 
 334 
The putative polysaccharide depolymerase (PD) activity exhibited by the phage used 335 
here [based on halo production around plaques (19); Fig 2], may be important in this 336 
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regard. These enzymes, expressed on the surface of phage capsids or produced by 337 
host cells during phage replication, are believed to facilitate phage attack on biofilm 338 
communities by enabling phage penetration of the exopolymeric matrix (19, 20). The 339 
bioengineering of phage T7 has already demonstrated the potential utility of PD 340 
expressing phage in biofilm dispersal (20), and it is possible any PD activity of phage 341 
used in this study may contribute to their ability to reduce crystalline biofilm formation 342 
and encrustation, independent of cell lysis.  343 
 344 
This highlights an additional feature of P. mirabilis phage that may be investigated 345 
further from the perspective of developing more broadly applicable anti-biofilm 346 
strategies. In the context of CAUTI, greater insights into the ability of phage to access 347 
biofilm associated cells could improve activity not only against mature biofilms, but 348 
perhaps more importantly multi-species biofilms. Challenges to the efficacy of phage 349 
therapy posed by multi-species biofilms would stem not only from the relatively 350 
narrow spectrum of activity of most phage, but also the possibility that mechanisms 351 
used by phage to access host bacterial cells within biofilms (such as PD enzymes), 352 
may be undermined by the chimeric EPS generated by multi-species biofilms (19).  353 
 354 
Although recent work does indicate the potential to tackle multi-species biofilms with 355 
phage therapy (17), it would seem the more detailed study of phage:biofilm 356 
interactions and elucidation of associated mechanisms, coupled with the powerful 357 
approach of phage genome engineering, holds much potential for enhancing the 358 
efficacy of phage therapy in this regard. Alternatively, the prophylactic administration 359 
of phage active against key pathogens such as P. mirabilis, should also serve to 360 
offset issues associated with access to target cells in multi-species or even single 361 
biofilms once these become established. Furthermore, there is also considerable 362 
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scope to combine phage therapy with other approaches to control infection such as 363 
antibiotics or other antimicrobial agents to enhance efficacy further. 364 
 365 
In summary, the current study supports the potential efficacy of phage therapy in 366 
control of CAUTI, and in particular blockage caused by P. mirabilis. Although there is 367 
a clear need for further fundamental research into phage:host interactions and the 368 
ability of phage to control CAUTI to progress this approach, our work also suggests a 369 
major factor in the successful use of phage therapy in this setting will be the parallel 370 
development of strategies to deliver sufficient numbers of phage within the most 371 
effective therapeutic window (e.g. early stage infection for P. mirabilis CAUTI). 372 
 373 
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FIGURE LEGENDS 454 
 455 
Figure 1: Illustration of in vitro bladder model system. Models were set-up 456 
according to specifications originally described by Stickler et al 1999 (12). a) Double 457 
walled glass vessel representing the bladder. b) Foley catheter inserted into the 458 
model and connected to drainage bag to form sterile closed drainage system. c) 459 
Drainage tubing. d) Drainage bag collects urine outflow. e) Sterile urine/artificial urine 460 
supplied to “bladder” via peristaltic pump at a constant flow rate. f) Water at 37 ˚C 461 
circulated through outer bladder model chamber to maintain constant temperature. 462 
Diagram is adapted from Stickler et al. 1999 (12). 463 
 464 
Figure 2: Example of plaque morphology and capsid morphology in P. mirabilis 465 
bacteriophage evaluated in bladder models. Images show plaque morphology for ΦRS1-466 
PmA, ΦRS1-PmB and ΦRS3-PmA generated on lawns of host strains used for isolation 467 
(Strain RS1 for ΦRS1-PmA and ΦRS1-PmB, and strain RS3 for ΦRS3-PmA). Associated 468 
transmission electron micrographs show structure of phage capsids, with morphology in all 469 
cases congruent with members of the Podoviridae family. 470 
 471 
Figure 3: Impact of bacteriophage treatment on catheter blockage. In vitro 472 
models of the catheterised urinary tract replicating either a late stage heavy infection 473 
(1010 cfu P. mirabilis), or early stage colonisation of the catheterised urinary tract (103 474 
cfu P. mirabilis), were used to evaluate the impact of a single phage therapy 475 
treatment on blockage and encrustation. For heavy infection test models were treated 476 
with phage at an MOI 1:1 phage:bacteria. Test models replicating early stage 477 
infection were treated with the same phage dose (MOI 1:10-7 phage:bacteria). Phage 478 
treatments were applied 45 min after models were inoculated with P. mirabilis. 479 
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Models were run until catheters became blocked and urine ceased to accumulate in 480 
drainage bags, or media was exhausted. A) Time taken for catheters in control and 481 
phage treated models to become blocked, or for media to be exhausted. B). pH of 482 
urine in residual bladder model media at end of experiments C) Enumeration of 483 
viable cells in residual urine in bladder models at the end of experiments. All data: 484 
Represent the means of 3 independent replicates. Error bars show the standard error 485 
of the mean. ** P < 0.01, **** P < 0.0001 Treated Vs Control in each model set-up. In 486 
models representing early infection and treated with phage no evidence of catheter 487 
blockage was observed and models were deactivated after 8 days when media was 488 
exhausted. 489 
 490 
Figure 4: Impact of phage treatment on crystalline biofilm formation. Models 491 
replicating a established infection (1010 cfu P. mirabilis) were used to evaluate the 492 
impact of phage treatment on crystalline biofilm formation. Test models were treated 493 
with phage at an MOI 1:1 phage:bacteria (1010 pfu:1010 cfu), 1h after model start. 494 
Both test and control models were deactivated after 10h and levels of crystalline 495 
biofilm formation measured on descending sections. A) Schematic of urethral 496 
catheter showing sections subject to analysis in part B. B) Quantification of crystalline 497 
biofilm formation and encrustation on catheter sections (total calcium present on 498 
each catheter section examined). Images below the chart provide examples of SEM 499 
visualisation of catheter cross-sections, distal to section 1-3, and levels of 500 
encrustation. Bars on SEM images represent 200 μm. C) pH of urine in residual 501 
bladder model media at end of experiments D) Enumeration of viable cells in residual 502 
urine in bladder models at the end of experiments – no significant differences. All 503 
data: Data represent the mean of three replicate experiments, and error bars show 504 
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the standard error of the mean. ** P < 0.01, *** P < 0.001 control section Vs phage 505 
treated model. 506 
Figure 1: Illustration of in vitro bladder model. Models were set-up according to specifications originally described by Stickler et al 1999 
(12). a) Double walled glass vessel representing the bladder. b) Foley catheter inserted into the model and connected to drainage bag to 
form sterile closed drainage system. c) Drainage tubing. d) Drainage bag collects urine outflow. e) Sterile urine/artificial urine supplied to 
“bladder” via peristaltic pump at a constant flow rate. f) Water at 37 ˚C circulated through outer bladder model chamber to maintain constant 
temperature. Diagram is adapted from Stickler et al. 1999 (12). 
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Figure'2:'Example'of'plaque'morphology'and'capsid'morphology' in'P.#mirabilis#bacteriophage'evaluated' in'bladder'models.' Images'show'plaque'
morphology'for'ΦRS16PmA,'ΦRS16PmB'and'ΦRS36PmA'generated'on'lawns'of'host'strains'used'for'isola@on'(Strain'RS1'for'ΦRS16PmA'and'ΦRS16PmB,'
and'strain'RS3'for'ΦRS36PmA).'Associated'transmission'electron'micrographs'show'structure'of'phage'capsids,'with'morphology'in'all'cases'congruent'
with'members'of'the'podoviridae'family.'
ΦRS1@PmA'
Phage'
morphology'
Plaque'
morphology'
10'nm'
10'nm'
10'nm'10'mm'
10'mm'
10'mm'
ΦRS3@PmA'
ΦRS1@PmB'
Established Infection Early Infection
100
101
102
103
104
105
106
107
108
109
Vi
ab
le
 c
el
ls
 (c
fu
/m
l)
Control Phage Treated
Established Infection Early Infection
0
2
4
6
8
10
pH
Control Phage Treated
Established Infection Early Infection
0
50
100
150
200
Ti
m
e 
to
 b
lo
ck
 (H
ou
rs
)
Control Phage Treated
A' B' C'
****'
****'
**'
****'>'8'days'
No'blockage'
Established Infection Early Infection
100
101
102
103
104
105
106
107
108
109
Vi
ab
le
 c
el
ls
 (c
fu
/m
l)
Control Phage Treated
Figure'3:'Impact'of'bacteriophage'treatment'on'catheter'blockage.'In+vitro'models'of'the'catheterised'urinary'tract'replica@ng'either'a'
late'stage'heavy'infec@on'(1010'cfu'P.+mirabilis),'or'early'stage'colonisa@on'of'the'catheterised'urinary'tract'(103'cfu+P.+mirabilis),'were'
used'to'evaluate'the'impact'of'a'single'phage'therapy'treatment'on'blockage'and'encrusta@on.'For'heavy'infec@on'test'models'were'
treated'with'phage'at'an'MOI'1:1'phage:bacteria.'Test'models'replica@ng'early'stage'infec@on'were'treated'with'the'same'phage'dose'
(MOI'1:1067'phage:bacteria).'Phage'treatments'were'applied'45'min'aQer'models'were' inoculated'with'P.+mirabilis.'Models'were'run'
un@l'catheters'became'blocked'and'urine'ceased'to'accumulate'in'drainage'bags,'or'media'was'exhausted.'A)'Time'taken'for'catheters'
in'control'and'phage'treated'models'to'become'blocked,'or'for'media'to'be'exhausted.'B).'pH'of'urine'in'residual'bladder'model'media'
at'end'of'experiments'C)'Enumera@on'of'viable'cells'in'residual'urine'in'bladder'models'at'the'end'of'experiments.'All'data:'Represent'
the'means'of'3'independent'replicates.'Error'bars'show'the'standard'error'of'the'mean.'**'P'<'0.01,'****'P'<'0.0001'Treated'Vs'Control'
in'each'model'set6up.'In'models'represen@ng'early'infec@on'and'treated'with'phage'no'evidence'of'catheter'blockage'was'observed'and'
models'were'deac@vated'aQer'8'days'when'media'was'exhausted.'
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Figure'4:' Impact'of'phage' treatment'on' crystalline'bioﬁlm' formaQon.'Models' replica@ng'a' established' infec@on' (1010'cfu'P.+mirabilis)'were'used' to'
evaluate'the'impact'of'phage'treatment'on'crystalline'bioﬁlm'forma@on.'Test'models'were'treated'with'phage'at'an'MOI'1:1'phage:bacteria'(1010'pfu:
1010' cfu),' 1h' aQer' model' start.' Both' test' and' control' models' were' deac@vated' aQer' 10h' and' levels' of' crystalline' bioﬁlm' forma@on' measured' on'
descending'sec@ons.'A)'Schema@c'of'urethral'catheter'showing'sec@ons'subject'to'analysis' in'part'B.'B)'Quan@ﬁca@on'of'crystalline'bioﬁlm'forma@on'
and' encrusta@on' on' catheter' sec@ons' (total' calcium'present' on' each' catheter' sec@on' examined).' Images' below' the' chart' provide' examples' of' SEM'
visualisa@on'of'catheter'cross6sec@ons,'distal'to'sec@on'163,'and'levels'of'encrusta@on.'Bars'on'SEM'images'represent'200'μm.'C)'pH'of'urine'in'residual'
bladder'model'media'at'end'of'experiments'D)'Enumera@on'of'viable'cells'in'residual'urine'in'bladder'models'at'the'end'of'experiments'–'no'signiﬁcant'
diﬀerences.'All'data:'Data'represent'the'mean'of'three'replicate'experiments,'and'error'bars'show'the'standard'error'of'the'mean.'**'P'<'0.01,'***'P'<'
0.001'control'sec@on'Vs'phage'treated'model.'
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